Real-time · AI · Cross-signal

Life Biosciences just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on Life Biosciences, plus every funding round, exec hire, and M&A move that follows, each with verified, ICP-ranked contacts.

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Get the full Deep Dive on Life Biosciences — free.

We'll email your report. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.

✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.

✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.

✕Clay enriches lists you built — No live signal of its own, no who or when.

✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.

Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Life Biosciences, Leading Developer Of Therapeutics For Aging-Related Diseases, Completes $82 Million Series C Financing Round

PRIVATEJan 05, 2022•over 4 years ago

Amount Raised

$82 Million

Round Type

series c

BostonBiotechnologyHealth Care

Description

Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the completion of a Series C financing of $82 million led by Alpha Wave Ventures. Senior management and founders invested in the Series C financing alongside longevity-oriented funds, seasoned investors, and experienced biotechnology scientists/entrepreneurs. Since its founding, Life Biosciences has raised over $158 million.

Company Information

Company

Life Biosciences

Location

Boston, Massachusetts, United States

About

Life Bio is a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. The company’s proprietary partial epigenetic reprogramming platform utilizes three transcription factors—Oct4, Sox2, and Klf4—to restore older and damaged cells to a younger state. This innovative approach targets a root cause of aging at the epigenetic level, thereby offering the potential to address a wide range of age-related diseases with significant unmet medical needs. Life Bio’s lead program, ER-100, is being developed as a gene therapy for optic neuropathies with plans to enter the clinic in 2025. Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential.

Related People

Suggested for you

2 contacts

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Life Biosciences's next move

Learn about Strategic plan

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Watching Life Biosciences? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demo Choose your plan